Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

被引：0
|
作者：
Daniel H. Deck
Jennifer M. Jordan
Thomas L. Holland
Weihong Fan
Matthew A. Wikler
Katherine A. Sulham
G. Ralph Corey
机构：
[1] The Medicines Company,
[2] Duke University Hospital,undefined
来源：
Infectious Diseases and Therapy | 2016年 / 5卷 / 3期
关键词：
D O I：
10.1007/s40121-016-0127-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：363 / 365
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis
    Zhang, Huan
    Zhou, Weiying
    Wang, Jin
    Cai, Yun
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 25 : 380 - 389
  • [22] Oritavancin (KIMYRSA™) in acute bacterial skin and skin structure infections: a profile of its use in the USA
    Young-A Heo
    Drugs & Therapy Perspectives, 2022, 38 : 57 - 63
  • [23] Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications
    Bassetti, Matteo
    Labate, Laura
    Vena, Antonio
    Giacobbe, Daniele R.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2021, 34 (02) : 96 - 108
  • [24] Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies
    Corey, G. Ralph
    Loutit, Jeffery
    Moeck, Greg
    Wikler, Matthew
    Dudley, Michael N.
    O'Riordan, William
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)
  • [25] Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Efficacy Summary
    O'Riordan, William
    Green, Sinikka
    Mehra, Purvi
    De Anda, Carisa
    Fang, Edward
    Prokocimer, Philippe
    CLINICAL INFECTIOUS DISEASES, 2014, 58 : S43 - S50
  • [26] Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations
    Lodise, Thomas P.
    Fan, Weihong
    Sulham, Katherine A.
    CLINICAL THERAPEUTICS, 2016, 38 (01) : 136 - 148
  • [27] A COMPARATIVE COST ANALYSIS BETWEEN DALBAVANCIN, ORITAVANCIN AND DELAFLOXACIN FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS IN SPAIN
    Rios, M.
    Carcedo, D.
    Sabaniego, J.
    Rossello, I
    VALUE IN HEALTH, 2023, 26 (12) : S86 - S86
  • [28] Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
    Leuthner, Kimberly D.
    Buechler, Kristin A.
    Kogan, David
    Saguros, Agafe
    Lee, H. Stephen
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 931 - 940
  • [29] Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus
    Corey, G. Ralph
    Arhin, Francis F.
    Wikler, Matthew A.
    Sahm, Daniel F.
    Kreiswirth, Barry N.
    Mediavilla, Jose R.
    Good, Samantha
    Fiset, Claude
    Jiang, Hai
    Moeck, Greg
    Kabler, Heidi
    Green, Sinikka
    O'Riordan, William
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (05) : 528 - 534
  • [30] EFFICACY AND HOSPITALIZATION LENGTH OF STAY OF SINGLE DOSE ORITAVANCIN COMPARED TO 7-10 DAYS OF VANCOMYCIN IN PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS IN THE US AND EASTERN EUROPE
    LaPensee, K.
    Fan, W.
    Fiset, C.
    Jiang, H.
    Lodise, T. P.
    VALUE IN HEALTH, 2014, 17 (07) : A664 - A664
12345